Muutke küpsiste eelistusi

E-raamat: Guide to Cell Therapy GxP: Quality Standards in the Development of Cell-Based Medicines in Non-pharmaceutical Environments

(R&D Director, XCELIA, Banc de Sang I Teixits, Barcelona, Spain), (Quality Assessment and GMP facilities Manager, Andalusian Initiative for Advanced Therapies, Consejeria de Salud, Junta de Andalucia, Sevilla, Spain)
  • Formaat: EPUB+DRM
  • Ilmumisaeg: 24-Jul-2015
  • Kirjastus: Academic Press Inc
  • Keel: eng
  • ISBN-13: 9780128031162
  • Formaat - EPUB+DRM
  • Hind: 103,73 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
  • Formaat: EPUB+DRM
  • Ilmumisaeg: 24-Jul-2015
  • Kirjastus: Academic Press Inc
  • Keel: eng
  • ISBN-13: 9780128031162

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

Guide to Cell Therapy GxP: Quality Standards in the Development of Cell-Based Medicines in Non-Pharmaceutical Environments provides a practical guide to the implementation of quality assurance systems for successful performance of all cell-based clinical trials.

The book includes all information that should be used in investigational medicinal product dossier (IMPD), the launching point for any clinical investigation, and beyond, bridging the gap in knowledge with the inclusion of examples of design of GLP-compliant preclinical studies, design of bioprocesses for autologous/allogeneic therapies, risk-based assessment of GMP-compliant processes for the production of cell-based therapies, and instructions on how to implement GLP/GMP standards in centers accredited with other quality assurance standards (JACIE; FACT/NETCORD, ISO9001, and others).

  • Provides easy access to important information on current regulations, state-of-the-art techniques, and recent advances otherwise scattered on various funding websites, within conference proceedings, or maintained in local knowledge
  • Features protocols, techniques for trouble-shooting common problems, and an explanation of the advantages and limitations of a technique in generating conclusive data
  • Includes practical examples of successful implementation of quality standards

Muu info

This book provides the quality standards used in the development of stem cell-based medicines in non-pharmaceutical environments, and includes all information that should be used in investigational medicinal product dossier (IMPD), the launching point for any clinical investigation.
List of Contributors
ix
Foreword xi
Preface xiii
1 Overview of the Development Program of a Cell-Based Medicine
1(14)
Arnau Pla
1 Introduction
1(3)
2 Key Pharmaceutical Factors to Consider in Early Development Stages
4(1)
3 TPP: Beginning with the End in Mind
5(1)
4 Stages of Drug Development
6(2)
5 Considering Stakeholders
8(1)
6 Product Lifecycle and Portfolio Management
9(1)
7 Performance Management and the Check Point Value
10(1)
8 Conclusions
11(4)
References
12(1)
Glossary
13(1)
List of Acronyms and Abbreviations
13(2)
2 European Regulatory Framework for the Development of Cell-Based Medicines
15(34)
Natividad Cuende
Ander Izeta
1 Introduction
16(1)
2 What Cell-Based Products are Considered as Medicinal Products? The Legal Definitions and Main Regulations Applying to Cell-Based Products
16(7)
3 An Introduction to Cell-Based Medicine Development: Roadmap
23(9)
4 Regional and National Institutions Supporting Cell Therapy Translational Research
32(1)
5 European Regulation for Advanced Therapy Medicinal Products Not Intended to be Placed on the Market: Hospital Exemption and Its National Interpretation
33(8)
6 Conclusions
41(8)
References
41(8)
3 Nonclinical Studies for Cell-Based Medicines
49(58)
Michaela Sharpe
Giulia Leoni
Jacqueline Barry
Rindi Schutte
Natalie Mount
1 Introduction
49(3)
2 Types of Cell-Based Advanced Therapy Medicinal Products and their Safety Considerations
52(5)
3 Regulations and Nonclinical Studies
57(3)
4 Nonclinical Assessment---The Risk-Based Approach
60(5)
5 The Requirement for Good Laboratory Practice
65(3)
6 General Study Design Considerations
68(11)
7 Specific Nonclinical Safety Considerations
79(19)
8 Conclusions
98(9)
References
99(5)
Glossary
104(1)
List of Acronyms and Abbreviations
105(2)
4 Good Manufacturing Practice Compliance in the Manufacture of Cell-Based Medicines
107(70)
Andy Romhild
1 Outline of the
Chapter
108(1)
2 Quality Management
109(4)
3 Documentation
113(7)
4 Qualification and Validation
120(9)
5 Premises and Equipment
129(8)
6 Personnel and Hygiene
137(10)
7 Manufacturing
147(10)
8 Quality Control
157(10)
9 Inspections, Audits, Complaints, Recalls, and Returns
167(4)
10 Conclusion
171(6)
Acknowledgment
171(1)
References
172(2)
List of Abbreviations
174(3)
5 Good Clinical Practice in Nonprofit Institutions
177(54)
Rosario C. Mata
Ana Cardesa
Fabiola Lora
1 Introduction
178(7)
2 The Elements of GCP Compliance
185(8)
3 The Clinical Trial Protocol
193(3)
4 The Investigator's Brochure
196(6)
5 The Informed Consent
202(2)
6 Essential Documents for Clinical Trial
204(8)
7 Clinical Trial Files
212(7)
8 Sponsor' Study Audit and Inspections
219(6)
9 Conclusion
225(6)
References
225(2)
Glossary
227(2)
List of Acronyms and Abbreviations
229(2)
6 Compatibility of GxP with Existing Cell Therapy Quality Standards
231
Roger Palau
Amy Lynnette Van Deusen
1 Quality Standards in Cell Therapy
232(2)
2 Adaptation of Existing Standards to GxP
234(8)
3 Impact of GxP Implementation
242(1)
4 Quality by Design
243(1)
5 Recommendations for Optimizing Integration of QA Systems
244(1)
6 Conclusions
245
References
246(3)
Glossary
249(2)
List of Abbreviations
251(2)
Index
253
Dr. Vives has specialties in GLP/GMP implementation, the development of (stem) cell-based products for regenerative medicine, and design, execution and analysis of non-clinical studies. He was a post-doctoral Fellow at University of Edinburgh and moved to Stem Cell Sciences Ltd in the UK where he became Head of Research. Six years ago, he became Head of Preclinical Studies at XCELIA, a biopharmaceutical company formed from The Catalan Blood and Tissue Service (Banc de Sang i Teixits) devoted to the development of advanced therapy medicine. As the Quality manager at XCelia, Dr. Vives secured the facility as the first GLP-compliant laboratory in Spain dedicated to the development of advanced cell therapies. He is now Director of R&D, responsible for technology transfer of innovative experimental bioprocesses into GMP-compliant production environments. He also manages GLP test facilities and relationships with Health Regulatory Agencies among other compliance responsibilities. Dr. Carmona is a Pharmacist with experience in management and training. She also holds a Masters Degree in Manufacturing of Advanced Therapy Medicinal Products and has worked across Europe in the biotechnology sector training on quality systems and good manufacturing practices in advanced therapies medicinal products. She has been a Quality Assessment Manager and GMP facilities Manager from the inception of the Andalusian Initiative for Advanced Therapies in October 2008. Previously, she worked worked as Quality Assessment and Accreditation Manager in the Andalusian Program for Cell Therapy and Regenerative Medicine. She has also worked as a Quality Assurance Technician at Cellerix an international biotech headquartered in Belgium, Cambridge, and Madrid and Clinical Documentation Technician in Pfizer.